Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 10, Issue 2, 2004, Pages 126-138

  Petkau, A John ^a   White, Richard A ^a   Ebers, George C ^b,m   Reder, Anthony T ^c   Sibley, William A ^d,k   Lublin, Fred D ^e,g   Paty, Donald W ^a   Duquette, Pierre ^f   Girard, Marc ^f   Despault, Liette ^f   DuBois, Renee ^f   Knobler, Robert L ^g   Kelley, Leith ^g   Francis, Gordon S ^h   Lapierre, Y ^h   Antel, Jack ^h   Freedman, Mark ^h   Hum, Stanley ^h   Greenstein, Jeffrey I ⁱ   Mishra, Bibhuti ⁱ   Muldoon, Joanne ⁱ   Whitaker, John N ^j   Evans, Bradley K ^j   Layton, Beverly ^j   Laguna, Joan ^k   Krikawa, John ^k   Oger, Joel J ^a   Kastrukoff, Lorne F ^a   Moore, G R Wayne ^a   Hashimoto, Stanley A ^a   Morrison, Wendy ^a   Nelson, Jill ^a   Goodin, Douglas S ^l   Massa, Stephen M ^l   Gutteridge, Elena ^l   Arnason, Barry G W ^c   Noronha, Avertano ^c   Martia, Roberta ^c   Rice, George P A ^m   Lesaux, Jane ^m   Johnson, Kenneth P ⁿ   Panitch, Hillel S ⁿ   Bever, Christopher T ⁿ   Conway, Kathleen ⁿ   Wallenberg, Joy Constine ^o   Bedell, Lisa ^o   van den Noort, Stanley ^p   Weinshenker, Brian ^q   Weiss, William ^r   Reingold, Stephen ^r   Pachner, Andrew ^s   Taylor, Wayne ^t   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f NOTRE DAME HOSPITAL   (Canada)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ TEMPLE UNIVERSITY HOSPITAL   (United States)

^j UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁿ UNIVERSITY OF MARYLAND   (United States)

^o BAYER PHARMA AG   (Germany)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q MAYO CLINIC   (United States)

^r National Multiple Sclerosis Society   (United States)

^s GEORGETOWN UNIVERSITY   (United States)

^t MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

EDSS scores; Exacerbation rates; Generalized estimating equations; Longitudinal data; T2 lesion burdens

Indexed keywords

INTERFERON BETA SERINE; NEOPTERIN; NEUTRALIZING ANTIBODY; PLACEBO; VIRUS PROTEIN;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DATA ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HEALTH STATUS; HUMAN; IMMUNOASSAY; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ORTHOMYXOVIRUS; PHYSICAL DISABILITY; RATING SCALE; SCORING SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES; DISABILITY EVALUATION; FEMALE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEOPTERIN; RECURRENCE; TREATMENT OUTCOME;

EID: 3042526220     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458504ms1004oa     Document Type: Article

References (27)

1. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
2. Files JG, Gray JL, Do LT, Foley WP, Gabe JD, Nestaas E et al. A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998; 18: 1019-24.
3. Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to interferon beta-1b. J Interferon Cytokine Res 1998; 18: 1025-30.
4. Arnason BG, Dianzani F. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: summary of an international workshop on anti-interferon antibodies. J Interferon Cytokine Res 1998; 18: 639-44.
5. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
6. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.
7. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Statist Med 1992; 11: 1825-39.
8. Liang KY, Zeger SL. Regression analysis for correlated data. Annu Rev Pub Health 1993; 14: 43-68.
9. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266-72.
10. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
11. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662-67.
12. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
13. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
14. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
15. European Study Group on Interferon β-1b in Secondary Progressive Multiple Sclerosis. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-97.
16. Goodkin DE, North American Study Group. Interferon β-1b in secondary progressive multiple sclerosis: clinical and MRI results of a 3-year randomized controlled trial (abstract). Neurology 2000; 54: 2352.
17. McFarland HF. Comparative analysis of the outcome of two phase III studies of interferon β-1b (abstract). Neurology 2000; 54: 2352.
18. SPECTRIMS (Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon β-1a in Multiple Sclerosis) Study Group. Randomized controlled trial of interferon β-1a in secondary progressive multiple sclerosis: clinical results. Neurology 2001; 56: 1496-504.
19. Calabresi PA, Frank JA, Maloni HW, Bash CN, Stone LA, McFarland HF et al. Association between neutralizing antibodies to interferon beta and contrast enhancing lesions in multiple sclerosis (abstract). Neurology 1997; 48: A80.
20. Oger JJF, Vorobeychick G, Al-Fahim A, Aziz T, Edan G, Paty DW et al. Neutralizing antibodies in Betaseron-treated multiple sclerosis patients and in vitro immune function before treatment (abstract). Neurology 1997; 48: A80.
21. Antonelli G, Bagnato F, Pozzilli C, Simeoni E, Bastianelli S, Currenti M et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a. J Interferon Cytokine Res 1998; 18: 345-50.
22. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann Neurol 1998; 43: 116-20.
23. Diggle PJ, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data, second edition. Oxford: Oxford University Press, 2002.
24. Oberg K, McKenna RM. The incidence and clinical significance of antibodies to interferon-β. In Reder AT ed., Interferon therapy of multiple sclerosis. New York: Marcel Dekker, 1997: 509-21.
25. Leroy V, Baud M, De Traversay C, Maynard-Muet M, Lebon P, Zarski JP et al. Role of interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 1998; 28: 375-81.
26. Hoffmann RM, Berg T, Teuber G, Prummer O, Leifeld L, Jung MC et al. Interferon antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. Z Gastroenterol 1999; 37: 715-23.
27. Rice GPA, Paszner B, Oger J, Lesaux J, Paty D, Ebers G et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277-79.